Fintel experiences that on April 25, 2023, Baird maintained protection of Applied Therapeutics (NASDAQ:APLT) with a Outperform advice.
Analyst Price Forecast Suggests 734.55% Upside
As of April 24, 2023, the common one-year price target for Applied Therapeutics is 9.18. The forecasts vary from a low of 4.04 to a excessive of $18.90. The common value goal represents a rise of 734.55% from its newest reported closing value of 1.10.
See our leaderboard of companies with the biggest value goal upside.
The projected annual income for Applied Therapeutics is 0MM. The projected annual non-GAAP EPS is -1.60.
What is the Fund Sentiment?
There are 70 funds or institutions reporting positions in Applied Therapeutics. This is a lower of 9 proprietor(s) or 11.39% within the final quarter. Average portfolio weight of all funds devoted to APLT is 0.06%, a rise of 369.66%. Total shares owned by establishments decreased within the final three months by 12.50% to 21,427K shares. The put/call ratio of APLT is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
Franklin Resources holds 4,775K shares representing 9.93% possession of the corporate. No change within the final quarter.
Orbimed Advisors holds 3,051K shares representing 6.34% possession of the corporate. In it is prior submitting, the agency reported proudly owning 4,250K shares, representing a lower of 39.30%. The agency decreased its portfolio allocation in APLT by 39.55% over the past quarter.
FBIOX – Biotechnology Portfolio holds 2,640K shares representing 5.49% possession of the corporate. In it is prior submitting, the agency reported proudly owning 3,335K shares, representing a lower of 26.35%. The agency decreased its portfolio allocation in APLT by 36.85% over the past quarter.
Knoll Capital Management holds 2,450K shares representing 5.09% possession of the corporate. In it is prior submitting, the agency reported proudly owning 1,082K shares, representing a rise of 55.83%. The agency elevated its portfolio allocation in APLT by 614.87% over the past quarter.
FBDIX – Franklin Biotechnology Discovery Fund holds 1,576K shares representing 3.27% possession of the corporate. No change within the final quarter.
Applied Therapeutics Background Information
(This description is offered by the corporate.)
Applied Therapeutics is a clinical-stage biopharmaceutical firm growing a pipeline of novel drug candidates towards validated molecular targets in indications of excessive unmet medical want. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the therapy of Galactosemia, a uncommon pediatric metabolic illness. The Company initiated a pivotal Phase 1/2 scientific trial in June 2019, learn out constructive top-line biomarker information in grownup Galactosemia sufferers in January 2020 and introduced full information from the trial in April 2020. A pediatric Galactosemia examine commenced in June 2020. The Company can be growing AT-001, a novel potent ARI that’s being developed for the therapy of Diabetic Cardiomyopathy, or DbCM, a deadly fibrosis of the guts. The Company initiated a Phase 3 registrational examine in DbCM in September 2019. The preclinical pipeline additionally consists of AT-003, an ARI designed to cross by the again of the attention when dosed orally, for the therapy of diabetic retinopathy, in addition to novel twin PI3k inhibitors in preclinical growth for orphan oncology indications.
See all Applied Therapeutics regulatory filings.
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.